Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma.

abstract：:Chronic myeloid leukemia therapy has remarkably improved with the use of frontline BCR-ABL kinase inhibitors such that newly diagnosed patients have minimal disease manifestations or progression. Effective control of disease may also set the stage for eventual 'cure' of this leukemia. However, the existence of Philade...

journal_title：Leukemia & lymphoma

authors： Donato NJ,Peterson LF

更新日期：2011-02-01 00:00:00

abstract：:Two important syndromes of hemophagocytic lymphohistiocytosis (HLH) have to be considered in infants and young children with recurrent fever, organomegaly and cytopenias. Familial hemophagocytic lymphohistiocytosis (FHLH) is a genetically heterogeneous autosomal recessive disease with histiocytic and lymphocytic infil...

journal_title：Leukemia & lymphoma

authors： Dürken M,Finckenstein FG,Janka GE

更新日期：2001-03-01 00:00:00

abstract：:After a first course of induction chemotherapy, 30-40% of patients with acute myeloid leukemia (AML) do not achieve a complete response (CR). A second course of an anthracycline and intermediate-dose cytarabine (IDAC) allows a significant number of patients with persistent AML at day 14 to finally achieve a CR. We hyp...

journal_title：Leukemia & lymphoma

authors： Prébet T,Jean E,Autret A,Charbonnier A,Rey J,Etienne A,D'incan E,Fürst S,Arnoulet C,Blaise D,Vey N

更新日期：2012-11-01 00:00:00

abstract：:Bone marrow scintigraphy is a simple and noninvasive examination useful to define the status of the bone marrow and spleen in polycythaemia vera (P.V.). Despite the absence of specificity of Indium 111 labelled transferrin (In-Tf) for myelopoietic tissue, there is a close correlation between bone marrow In-Tf uptake a...

journal_title：Leukemia & lymphoma

authors： Rain JD,Najean Y,Billotey C

更新日期：1996-09-01 00:00:00

abstract：:We have previously described a relation between abundance of eosinophilic granulocytes in Hodgkin's disease (HD) tumours and poor prognosis. In order to further explore the importance of the eosinophilic infiltration, we immunohistochemically examined the presence of eosinophils, using the monoclonal antibodies EG 1 a...

journal_title：Leukemia & lymphoma

authors： Molin D,Glimelius B,Sundström C,Venge P,Enblad G

更新日期：2001-07-01 00:00:00

abstract：:This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one week prior to Cycle 1 (C1) of ICE and during two weeks of C1-2 of ICE...

journal_title：Leukemia & lymphoma

authors： Hu B,Younes A,Westin JR,Turturro F,Claret L,Feng L,Fowler N,Neelapu S,Romaguera J,Hagemeister FB,Rodriguez MA,Samaniego F,Fayad LE,Copeland AR,Nastoupil LJ,Nieto Y,Fanale MA,Oki Y

更新日期：2018-04-01 00:00:00

abstract：:Tumor necrosis factor (TNF) is a major regulator of AML growth in vitro and markedly enhances AML growth induced by GM-CSF/IL-3. TNF, on the other hand, suppresses the G-CSF stimulated AML cell proliferation and serves as a modulator of growth factor receptors on AML cells. It upregulates GM-CSF and IL-3 receptors by ...

journal_title：Leukemia & lymphoma

authors： Elbaz O,Mahmoud LA

更新日期：1994-01-01 00:00:00

abstract：:Several surveys have defined chronic lymphocytic leukemia (CLL) patients as a high-risk patient population for developing second neoplasms. As possible mechanisms underlying the increased risk of specific second malignancies in CLL patients the immunodeficiency associated with disease is generally proposed. As far as ...

journal_title：Leukemia & lymphoma

authors： Molica S

更新日期：2005-01-01 00:00:00

abstract：:Despite individual differences between certain leukemias, the overall survival rate in acute leukemia remains low at approximately 40%. Novel therapeutics, including targeted therapies like tyrosine kinase inhibitors, have been incorporated into treatment regimens, but most have failed at eradicating leukemic stem cel...

journal_title：Leukemia & lymphoma

authors： Karantanou C,Godavarthy PS,Krause DS

更新日期：2018-11-01 00:00:00

abstract：:Male gender was recently reported as an adverse prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). We conducted a retrospective study of adult patients with DLBCL initially treated with rituximab containin...

journal_title：Leukemia & lymphoma

authors： Carella AM,de Souza CA,Luminari S,Marcheselli L,Chiappella A,di Rocco A,Cesaretti M,Rossi A,Rigacci L,Gaidano G,Merli F,Spina M,Stelitano C,Hohaus S,Barbui A,Puccini B,Miranda EC,Guida A,Federico M

更新日期：2013-01-01 00:00:00

abstract：:The short segments of cDNA encoding glycoprotein (GP)Ib alpha, GPIIb, GPIIIa and platelet factor (PF) 4 were amplified using reverse transcriptase-polymerase chain reaction (RT-PCR) in order to characterize various types of megakaryoblasts. Cell lines with megakaryocytic features (K562, CMK and HEL) were tested. GPIb ...

journal_title：Leukemia & lymphoma

authors： Yasunaga M,Ryo R,Sugano W,Yamaguchi N

更新日期：1992-08-01 00:00:00

abstract：:Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of hematological cancers, in particular multiple myeloma (MM). Both drugs reveal a dual mechanism of action: they target tumour cells by direct cytotoxicity and, indir...

journal_title：Leukemia & lymphoma

authors： Vallet S,Palumbo A,Raje N,Boccadoro M,Anderson KC

更新日期：2008-07-01 00:00:00

abstract：:Dysregulation of MYBL2 has been associated to tumorigenesis and the S427G polymorphism could induce partial inactivation of MYBL2, associating it with cancer risk. It has previously been shown that MYBL2 was over-expressed in some acute myeloid leukemias (AML), portending poor prognosis. However, to date no studies ha...

journal_title：Leukemia & lymphoma

authors： Dolz S,García P,Llop M,Fuster Ó,Luna I,Ibáñez M,Gómez I,López M,Such E,Cervera J,Sanz MA,De Juan I,Palanca S,Murria R,Bolufer P,Barragán E

更新日期：2016-02-01 00:00:00

abstract：:In the HOVON68 CLL trial, patients 65 to 75 years of age had no survival benefit from the addition of low-dose alemtuzumab to fludarabine and cyclophosphamide (FC) in contrast to younger patients. The reasons are explored in this 5-year trial update using both survival analysis and competing risk analysis on non-CLL-r...

journal_title：Leukemia & lymphoma

authors： Vojdeman FJ,Van't Veer MB,Tjønnfjord GE,Itälä-Remes M,Kimby E,Polliack A,Wu KL,Doorduijn JK,Alemayehu WG,Wittebol S,Kozak T,Walewski J,Abrahamse-Testroote MC,van Oers MH,Geisler CH

更新日期：2017-03-01 00:00:00

abstract：:We report results of a randomized, phase III study of ofatumumab versus physicians' choice treatment in patients with bulky fludarabine-refractory chronic lymphocytic leukemia and explore extended versus standard-length ofatumumab treatment. Patients (79 ofatumumab, 43 physicians' choice) completed a median 6 (ofatumu...

journal_title：Leukemia & lymphoma

authors： Österborg A,Udvardy M,Zaritskey A,Andersson PO,Grosicki S,Mazur G,Kaplan P,Steurer M,Schuh A,Montillo M,Kryachok I,Middeke JM,Kulyaba Y,Rekhtman G,Gorczyca M,Daly S,Chang CN,Lisby S,Gupta I

更新日期：2016-09-01 00:00:00

abstract：:The importance of obtaining a tumor-free graft for autologous transplantation in cancer patients has been debated extensively in the last decade and is still unresolved largely because it is believed that relapse is more likely to originate from the host and not from the graft. This is in spite of recent indications t...

journal_title：Leukemia & lymphoma

authors： Gazitt Y,Reading CL

更新日期：1996-10-01 00:00:00

abstract：:Eighteen patients (pts) with myelodysplastic syndrome (MDS) were treated with thymopentin (TP) (50 mg subcutaneously for 5 days) and recombinant interferon alpha 2a (rIFN alpha 2a) (3 MU/m2 subcutaneously on the sixth day); the courses were delivered every week. Moreover those pts with > or = 10% blasts in the bone ma...

journal_title：Leukemia & lymphoma

authors： Venditti A,Scimò MT,del Poeta G,Buccisano F,Stasi R,Mastino A,Grelli S,Favalli C,Garaci E,Papa G

更新日期：1995-01-01 00:00:00

abstract：:We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having...

journal_title：Leukemia & lymphoma

authors： Shah GL,Landau H,Londono D,Devlin SM,Kosuri S,Lesokhin AM,Lendvai N,Hassoun H,Chung DJ,Koehne G,Jhanwar SC,Landgren O,Levine R,Giralt SA

更新日期：2017-08-01 00:00:00

abstract：:Mini-transplant has been used popularly in recent years. The intensity of conditioning regimens is less in mini-transplant, thus the anti-tumor effect is mainly carried by an immunological reaction, called graft-versus-leukemia (GVL)/graft-versus-tumor (GVT) effect. Thus, graft-versus-host disease (GVHD) in mini-trans...

journal_title：Leukemia & lymphoma

authors： Mineishi S,Schuening FG

更新日期：2004-10-01 00:00:00

abstract：:Gene array studies on follicular lymphoma (FL) have associated non-malignant tumor-infiltrating immune cells with patient survival. We examined the role of such cells detectable by immunohistochemistry in a tissue microarray, focusing on plasmacytoid dendritic cells (pDCs). These cells physiologically produce interfer...

journal_title：Leukemia & lymphoma

authors： Butsch R,Lukas Waelti S,Schaerer S,Braun J,Korol D,Probst-Hensch N,Moch H,Kurrer M

更新日期：2011-07-01 00:00:00

abstract：:The occurrence of unexplained peripheral blood cytopenia, particularly neutropenia, has been recently reported after rituximab. Its prevalence may be underestimated since it may occur late after treatment. This study analysed all cases of unexplained delayed-onset peripheral blood cytopenia of WHO grade II - IV occurr...

journal_title：Leukemia & lymphoma

authors： Cattaneo C,Spedini P,Casari S,Re A,Tucci A,Borlenghi E,Ungari M,Ruggeri G,Rossi G

更新日期：2006-06-01 00:00:00

abstract：:A two-year-old boy presented with pancytopenia. Bone marrow examination revealed an aplastic marrow with prominent immature plasma cell proliferation, which mimicked plasma cell leukemia. Immunohistochemistry, however, revealed a polyclonal population consistent with a reactive process, excluding plasma cell neoplasia...

journal_title：Leukemia & lymphoma

authors： Kikuchi M,Ohsaka A,Chiba Y,Sato M,Muraosa Y,Hoshino H

更新日期：1999-09-01 00:00:00

abstract：:Clonal bone marrow (BM) B-cell populations are a common finding in patients with suspected primary central nervous system lymphoma (PCNSL). To assess their clinical significance, benign monoclonal B-cell lymphocytosis (MBL) needs to be differentiated from concomitant BM involvement, since patients with secondary centr...

journal_title：Leukemia & lymphoma

authors： Brandt A,Matschke J,Fehrle W,von Wenserski L,Bokemeyer C,Illerhaus G,Binder M

更新日期：2019-02-01 00:00:00

abstract：:We treated 15 patients with therapy related acute nonlymphocytic leukemia (tANLL) or therapy related myelodysplastic syndrome (tMDS) who had no rearrangements of chromosomes 5 and/or 7 or complex cytogenetic rearrangements by intensive chemotherapy. The median age was 43 years. Seven patients had one of the "specific"...

journal_title：Leukemia & lymphoma

authors： Fenaux P,Laï JL,Quiquandon I,Preudhomme C,Dupriez B,Facon T,Lorthois C,Lucidarme D,Bauters F

更新日期：1991-01-01 00:00:00

abstract：:We describe a patient with acute promyelocytic leukemia (APL) who developed pulmonary embolism (PE) and thrombotic thrombocytopenic purpura (TTP) during remission induction all-trans retinoic acid (ATRA) therapy. A 44-year-old man was diagnosed with APL and was treated with ATRA. On day 14, he developed PE, and on day...

journal_title：Leukemia & lymphoma

authors： Fujita H,Takemura S,Hyo R,Tanaka M,Koharazawa H,Fujisawa S,Kanamori H,Ishigatsubo Y

更新日期：2003-09-01 00:00:00

abstract：:Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clinical phase I/II trials, blinatumomab showed remarkable single-agent a...

journal_title：Leukemia & lymphoma

authors： Goebeler ME,Bargou R

更新日期：2016-05-01 00:00:00

abstract：:Natural killer (NK) cells are the subject of great current interest because of their possible (in vivo) role in tumour cell surveillance and killing, and because of the potential application of cytokine-modulated NK cells in cancer immunotherapy. In addition, clonal proliferations of NK-associated (NKa) cell populatio...

journal_title：Leukemia & lymphoma

authors： Richards SJ,Scott CS

更新日期：1992-08-01 00:00:00

abstract：:Hodgkin lymphoma (HL) has become a highly curable malignancy even in advanced stages when treated adequately. However, relapsed or refractory disease and treatment-related toxicity constitute a significant clinical challenge. Innovative approaches are thus needed to improve treatment of these mainly young patients. In...

journal_title：Leukemia & lymphoma

authors： Bröckelmann PJ,Borchmann P,Engert A

更新日期：2016-09-01 00:00:00

abstract：:An early intensive anthracycline therapy can improve therapeutic outcome in adult acute lymphoblastic leukaemia (ALL) but is usually associated with marked myelosuppressive effects and significant morbidity by infections. To reduce this risk, we employed granulocyte colony-stimulating factor (G-CSF, filgrastim 5 micro...

journal_title：Leukemia & lymphoma

authors： Bassan R,Lerede T,Di Bona E,Rossi G,Pogliani E,Rambaldi A,Buelli M,Viero P,Rodeghiero F,Izzi T,Corneo G,Barbui T

更新日期：1997-06-01 00:00:00

abstract：:The WT1 gene is essential for kidney development and is mutated in some Wilms tumours. It is also expressed at a high level in many acute leukaemias and in some haematopoietic progenitor cells, and mutations have been found in leukaemias. The function of WT1, which is a zinc finger protein and has domains characterist...

journal_title：Leukemia & lymphoma

authors： Pritchard-Jones K,King-Underwood L

更新日期：1997-10-01 00:00:00